Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Down 5.1% - Time to Sell?

Key Points

• Teva Pharmaceutical Industries' shares fell 5.1% to $18.91 amid fluctuating trading volume, significantly below the average session volume.
• Wall Street analysts have varied opinions with several rating the stock as a buy, including Goldman Sachs who set a price target of $24.00, while UBS reduced its target to $23.00.
• Teva's latest earnings report showed a profit of $0.66 per share, beating estimates, but revenue was slightly below expectations at $4.18 billion.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) shares fell 5.1% during mid-day trading on Monday . The stock traded as low as $18.99 and last traded at $18.91. 9,188,954 shares traded hands during mid-day trading, a decline of 23% from the average session volume of 11,960,685 shares. The stock had previously closed at $19.93.

Wall Street Analyst Weigh In

Several brokerages have issued reports on TEVA. Truist Financial began coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price target on the stock. The Goldman Sachs Group began coverage on Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a "buy" rating and a $24.00 price target on the stock. UBS Group dropped their price target on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. Finally, Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Two equities research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $24.71.

Teva Pharmaceutical Industries Trading Down 0.4%

The stock has a market capitalization of $21.08 billion, a P/E ratio of -114.88, a price-to-earnings-growth ratio of 1.07 and a beta of 0.72. The stock has a 50-day moving average price of $17.51 and a two-hundred day moving average price of $16.58. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. The company had revenue of $4.18 billion during the quarter, compared to analysts' expectations of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm's revenue for the quarter was up .3% compared to the same quarter last year. During the same quarter last year, the business posted $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the completion of the sale, the insider owned 6,774 shares of the company's stock, valued at approximately $102,693.84. This trade represents a 47.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. 0.49% of the stock is currently owned by insiders.

Institutional Trading of Teva Pharmaceutical Industries

Hedge funds have recently bought and sold shares of the stock. Golden State Wealth Management LLC bought a new stake in Teva Pharmaceutical Industries during the first quarter valued at about $39,000. Advisors Asset Management Inc. bought a new stake in Teva Pharmaceutical Industries during the second quarter valued at about $41,000. New Age Alpha Advisors LLC bought a new stake in Teva Pharmaceutical Industries during the first quarter valued at about $43,000. Sound Income Strategies LLC grew its holdings in Teva Pharmaceutical Industries by 3,715.8% during the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company's stock valued at $49,000 after purchasing an additional 2,824 shares during the period. Finally, Compagnie Lombard Odier SCmA bought a new stake in Teva Pharmaceutical Industries during the first quarter valued at about $54,000. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.